Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| CD7-R52H9 | Rat | Rat CD27 / TNFRSF7 Protein, His Tag |  |
|
|
| CD7-H522b | Human | Human CD27 / TNFRSF7 Protein, His Tag (MALS verified) |  |
|
|
| CD7-M5252 | Mouse | Mouse CD27 / TNFRSF7 Protein, Mouse IgG2a Fc Tag, low endotoxin |  |
|
|
| CD7-H5257 | Human | Human CD27 / TNFRSF7 Protein, Mouse IgG2a Fc Tag, low endotoxin (MALS verified) |  |
|
|
| CD7-C5259 | Cynomolgus / Rhesus macaque | Cynomolgus / Rhesus macaque CD27 / TNFRSF7 Protein, Mouse IgG2a Fc Tag, low endotoxin |  |
|
|
| TN7-H82F6 | Human | Biotinylated Human CD27 / TNFRSF7 Protein, Fc,Avitag™ |  |
|
|
| CD7-H5254 | Human | Human CD27 / TNFRSF7 Protein, Fc Tag (HPLC verified) |  |
|
|
Flow Cytometry assay shows that Human CD27 Protein, Mouse IgG2a Fc Tag (Cat. No. CD7-H5257) can bind to Raji cells Surface Human CD70. The concentration of CD27 used is 10 μg/mL (Routinely tested).
Immobilized Human CD27, His Tag (Cat. No. CD7-H522b) at 2 μg/mL (100 μL/well) can bind Biotinylated Human CD27 Ligand Protein, Avitag,Fc Tag with a linear range of 1-31 ng/mL (QC tested).
The purity of Human CD27, His Tag (Cat. No. CD7-H522b) is more than 85% and the molecular weight of this protein is around 32-47 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Boserolimab | MK-5890 | Phase 2 Clinical | Aduro Biotech Europe Bv | Solid tumours; Triple Negative Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Varlilumab | CDX-1127 | Phase 2 Clinical | Celldex Therapeutics | Lung Neoplasms; Lymphoma, Primary Effusion; Cholangiocarcinoma; Prostatic Neoplasms; Bile Duct Neoplasms; Urologic Neoplasms; Astrocytoma; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Gallbladder Neoplasms; Lymphoma, T-Cell; Plasmablastic Lymphoma; Urogenital Neoplasms; Glioma; Leukemia, Lymphocytic, Chronic, B-Cell; Melanoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Leukemia, T-Cell; Large intestine neoplasm; Central Nervous System Lymphoma; Skin Neoplasms; Solid tumours; Kidney Neoplasms; Head and Neck Neoplasms; Lymphoma, B-Cell, Marginal Zone; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Lymphomatoid Granulomatosis; Lymphoma, Large B-Cell, Diffuse; Lymphoma, B-Cell; Glioblastoma; Neoplasms; Kidney Diseases; Triple Negative Breast Neoplasms; Hormone-Resistant Prostate Neoplasms; Urinary Bladder Neoplasms; Urologic Diseases; Oligodendroglioma; Lymphoma, Mantle-Cell | Details |
| LOR-S03 | CDX-527 | Phase 1 Clinical | Celldex Therapeutics | Ovarian Neoplasms; Liver Neoplasms; Solid tumours; Head and Neck Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Breast Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Anti-CD27 monoclonal antibody (Aduro Biotech) | BION-1402 | Phase 1 Clinical | Aduro Biotech Inc | Neoplasms | Details |
This web search service is supported by Google Inc.
A-Z
